Interim Reports
Latest Reports
-
Interim Report 2 2021/22
Strong sales growth for the 3rd consecutive quarter. Recent advancements in regenerative medicine create additional growth potential in clinical applications for the company.
-
Interim Report 1 2021/22
The strategic shift of sales and marketing continues to prove itself. Despite being a “slow summer quarter”, sales during May – July surpassed sales during any previous quarter.
-
Year-end Report 2020/21
The strategic shift to focus on digital sales & marketing has been successful, reflected in the sales increase during the latter part of the fiscal year.
-
Interim Report 3 (2020-11-01 – 2021-01-31)
The second wave of the pandemic restricted sales during the 3rd quarter. However, the situation has improved significantly since late January.